Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay

Journal of Urology

Volumn 186, Issue 5, 2011, Pages 2101-2106

  Baden, Jonathan ^a   Adams, Scott ^a   Astacio, Tara ^a   Jones, Jennifer ^a   Markiewicz, Jadwiga ^a   Painter, Jennifer ^a   Trust, Carrie ^a   Wang, Yixin ^a   Green, George ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

diagnosis; epigenesis; genetic; methylation; prostate; prostatic neoplasms

Indexed keywords

APC PROTEIN; GLUTATHIONE TRANSFERASE P1; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID RECEPTOR BETA; TUMOR MARKER;

ACCURACY; ALGORITHM; ARTICLE; ASSAY; CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; EPIGENETICS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK FACTOR; TUMOR VOLUME;

ADENOMATOUS POLYPOSIS COLI; ADULT; AGED; ALGORITHMS; BIOLOGICAL ASSAY; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 80053945736     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.06.052     Document Type: Article

References (23)

1. Cancer Facts and Figures 2009 American Cancer Society Atlanta 4
2. W.H. Cooner, B.R. Mosley, and C.L. Rutherford Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen J Urol 143 1990 1146
3. B.M. Mian, Y. Naya, and K. Okihara Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy Urology 60 2002 836
4. W.J. Catalona, D.S. Smith, and D.K. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination Enhancement of specificity with free PSA measurements JAMA 277 1997 1452
5. F.H. Schröder, J. Hugosson, M.J. Roobol ERSPC Investigators Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320
6. G.L. Andriole, E.D. Crawford, and R.L. Grubb 3rd Mortality results from a randomized prostate-cancer screening trial PLCO Project Team N Engl J Med 360 2009 1310
7. P. Carroll, P.C. Albertsen, and K. Greene Prostate-Specific Antigen Best Practice Statement: 2009 Update 2009 American Urological Association Education and Research Linthicum
8. T. Piironen, K. Pettersson, and M. Suonpaa In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples Urology 48 1996 81
9. H. Lilja, A. Haese, and T. Bjork Significance and metabolism of complexed and noncomplexed prostate specific antigen forms and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy J Urol 162 1999 2029
10. R.G. Nixon, M.H. Wener, and K.M.B. Smith Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients J Urol 157 1997 2183
11. F. Recker, M.K. Kwiatkowski, and T. Piironen Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen Urology 55 2000 481
12. A. Haese, M. Graefen, and C. Becker The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer Prostate 54 2003 181
13. I.L. Deras, S.M.J. Aubin, and A. Blase PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587
14. L.S. Marks, Y. Fradet, and I.L. Deras PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy J Urol 69 2007 532
15. V.L. Costa, R. Henrique, and C. Jerónimo Epigenetic markers for molecular detection of prostate cancer Dis Markers 23 2007 31
16. P.J. Bastian, G.S. Palapattu, and X. Lin Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy Clin Cancer Res 11 2005 4037
17. M.O. Hoque, O. Topaloglu, and S. Begum Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects J Clin Oncol 23 2005 6569
18. T. Vener, C. Derecho, and J. Baden Development of a multiplexed urine assay for prostate cancer diagnosis Clin Chem 54 2008 874
19. J. Baden, G. Green, and J. Painter A multicenter evaluation of an investigational prostate cancer methylation assay J Urol 182 2009 825
20. I.M. Thompson, D.P. Ankerst, and C. Chi Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 2006 529
21. D.V. Makarov, S. Loeb, and R.H. Getzenberg Biomarkers for prostate cancer Annu Rev Med 60 2009 139
22. C. Schlesinger, D.G. Bostwick, and K.A. Iczkowski High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice Am J Surg Pathol 29 2005 1548
23. A.M. Cronin, and A.J. Vickers Statistical methods to correct for verification bias in diagnostic studies are inadequate when there are few false negatives: a simulation study BMC Med Res Methodol 8 2008 75